ClinicalTrials.gg
RecruitingNCT07863180BUTTER2Updated Nov 5, 2026

Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial

A Phase 1/2 interventional study of Tributyrin and Placebo in Parkinson Disease, Multiple System Atrophy and Progressive Supranuclear Palsy(PSP), sponsored by Prabesh Kanel. Recruiting at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Prabesh Kanel · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 5, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,650 studies in Parkinson Disease with a site in United States — 305 open to participants now, 387 under way, 7 of them phase 3. Parkinson Disease · United States.

Planned enrollment
964th of 1,257
15 · median 36
Started
2026
with 83 others
Phase 1/2
51 of 1,650
11 open now
Primary completion
2027-05
later than 163 of 384 live
Registered
1,644th of 1,650
by date

Among the 1,650 studies in Parkinson Disease with a site in United States, this one is the 964th largest by planned enrollment of the 1,257 interventional ones that give a count, is one of 84 that started in 2026, is one of 51 in phase 1/2, reaches primary completion later than 163 of the 384 other live ones, and was the 1,644th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

305 of the 1,650 studies in Parkinson Disease with a site in United States are open now. Recruiting first, the newest first:

299 more — sign in →

All 305 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,650 studies in Parkinson Disease with a site in United States, or all of them as a file.
02

Study summary

This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.

Read the detailed description

This is a sub-study of NCT07154511.

03

Conditions studied

  • Parkinson Disease
  • Multiple System Atrophy
  • Progressive Supranuclear Palsy(PSP)

Keywords

  • short chain fatty acid
  • fecal microbiota transplantation
  • Butyric acid
  • Tributyrin
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female, age 45 years and over.
  • Diagnosis of PSP-Richardson syndrome (RS) based on Movement Disorder Society (MDS) Criteria, including

    1. Vertical supranuclear gaze palsy.
    2. Repeated unprovoked falls OR tendency to fall on the pull test within 3 years.
  • Access to the internet and webcam for virtual visits.
  • Presence of a caregiver.

Exclusion criteria

Exclusion Criteria:

  • Recent history of significant, uncontrolled GI disease such as Gastroesophageal reflux disease, colorectal cancer.
  • Significant metabolic or uncontrolled medical comorbidity.
  • Regular use of typical anti-cholinergic drugs.
  • Women of , or who are pregnant and/or nursing.
  • Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory.
  • Any other condition or criterion that, in the opinion of the investigators, would preclude safe and meaningful participation in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Tributyrin

    Participants will take 500mg three times a day (TID) tributyrin supplement for 90 days +/- 7 days.

    Drug: Tributyrin

  • Placebo comparator
    Placebo

    Participants will take 500mg placebo for 90 days +/- 7 days.

    Drug: Placebo

Interventions

  • Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 90 days +/- 7 days.

  • DrugPlacebo

    Participants will take 500mg TID placebo for 90 days +/- 7 days.

06

What researchers measure

Primary outcomes

  1. Tolerability of tributyrin

    Tolerability will be defined as the percent of patients that dropped out of the study. (# enrolled at baseline-# enrolled on visit 7)/# enrolled at baseline

    Time frame: Visit 7 (approximately day 90)

  2. Safety of tributyrin

    Safety will be defined as the percent of patients who experienced serious adverse events.

    Time frame: Up to visit 7 (approximately day 90)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for May 2027, 7 months after the start.

Of 55 phase 1/2 interventional studies under Parkinson Disease, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 53. This study's planned 7 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartActual
Oct 1, 2026was Sep 2026
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Oct 1, 2026 (actual)
Nov 5, 2026
Registered
First appeared on the registry
Oct 7, 2026
Show all 2 updates
  1. Nov 5, 2026
    Start date Sep 2026→Oct 1, 2026 (now actual)
  2. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07863180
Lead sponsor
Prabesh Kanel
Collaborators
Farmer Family Foundation
Responsible party
Prabesh Kanel (Research Assistant Professor of Radiology, University of Michigan) — Sponsor-investigator
First posted
Oct 7, 2026
Start date
Oct 1, 2026
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Nathan Alexander
Contact
natealex@med.umich.edu
734-998-8422
Robert Vangel, BSc
Contact
rvangel@med.umich.edu
734-936-1168
Prabesh Kanel, PhD
principal investigator · University of Michigan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tributyrin

Start the discussion